News und Analysen

Veeva Systems(NYSE:VEEV) reported fiscal second quarter 2026 results on August 27, 2025, delivering $789 million in revenue and raising full-year billings guidance by $35 million. The quarter

Agilent Technologies(NYSE:A) reported Q3 FY2025 revenue of $1.74 billion, up 6.1% year-over-year on a core basis, with non-GAAP EPS of $1.37, both exceeding guidance. The company raised its

Shares of EchoStar (NASDAQ: SATS) jumped on Wednesday, closing the day up 15.5%. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) both ticked up

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other semiconductor stocks. To learn more, check out the short video, consider

This year has offered no shortage of market-moving headlines shaping investor sentiment. Mixed job reports, new tariffs fueling turbulence in U.S. trade policy, and ongoing uncertainty around

Viking Therapeutics (NASDAQ: VKTX) announced trial results for its weight loss pill that disappointed stock market investors.

*Stock prices used were the afternoon prices of Aug. 24, 2025. The

Telecom giant AT&T (NYSE: T) struck a deal with EchoStar on Tuesday to acquire wireless spectrum licenses that cover nearly ever market across the U.S. The company will pay $23 billion for 30 MHz of

U.S. equity markets rose broadly on Tuesday as optimism over monetary policy, upbeat corporate news, and anticipation of Nvidia (NASDAQ: NVDA)'s earnings propelled gains. The S&P 500 added 0.41%

When it comes to growth stocks, you have to understand the risks going in. But there are three growth stocks that I have strong convictions about, and they could produce huge returns for investors.

Viking Therapeutics (NASDAQ: VKTX) delivered one of the most anticipated obesity readouts of the year -- and Wall Street promptly panicked. Shares plummeted 40% after the company released Phase 2

Dividend investing can be tricky, since income-focused investors want to find high yields while also avoiding stocks that end up cutting their quarterly payouts. There's a balance that has to be

Vertex Pharmaceuticals (NASDAQ: VRTX) is usually a market-beater, but it hasn't been so over the past year. The company's shares are down 18% over the trailing-12-month period due to a combination

Dividend stocks aren't all created equal. Some decrease their payouts, or suspend them altogether, when they face headwinds. Others have much stronger businesses and continue to raise their

Viking Therapeutics (NASDAQ: VKTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the

While the market is full of varying perspectives from many different investors, the "smart money" is still held in high regard. By smart money, I mean professional investors, many of whom run their

Amid competition in the cruise line industry, investors seem to have overlooked Royal Caribbean (NYSE: RCL). The larger market share of Carnival and the relatively recent IPO of Viking Holdings seem

How does getting paid to own a stock sound to you? That's exactly what dividends do. Even if you don't need extra income, reinvesting dividends can significantly increase the total returns you

The old saying that "birds of a feather flock together" doesn't always apply to the world of the super-wealthy. Rich investors often follow their own paths rather than buying the same assets. So

Shares in Viking Therapeutics (NASDAQ: VKTX) crashed by 35.9% in the week to Friday morning. The decline comes in a week when the company released its top-line results from its phase 2 trial of its

I happily own stock in Medtronic (NYSE: MDT), one of the largest medical device makers in the world. Of late, the company is struggling through a rough patch that has Wall Street worried about the

Nvidia (NASDAQ: NVDA) closed down 0.2% at $174.98 on Thursday, with trading volume of 135 million shares, below its three-month average of 181 million. The modest decline contrasted with weakness in

The use of robotics in surgery is on the rise. The market was valued at $800 million in 2015, and has since risen to over $3 billion. One reason behind this rapid growth is that these robot systems

As of Aug. 20, shares of Viking Therapeutics (NASDAQ: VKTX) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting to new clinical trial results regarding its

Dividend Champions are known for their reliability. These companies have raised their dividends annually for at least 25 years. Some remain overlooked by investors because they don't need to be in